Detalhe da pesquisa
1.
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Cancer Immunol Immunother
; 73(3): 60, 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400933
2.
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
JAMA
; 330(20): 1961-1970, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38015220
3.
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Oncologist
; 26(3): e484-e491, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33044793
4.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196068
5.
Safety of same-day discharge after uncomplicated, minimalist transcatheter aortic valve replacement in the COVID-19 era.
Catheter Cardiovasc Interv
; 97(5): 940-947, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382519
6.
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Oncologist
; 25(4): 348-354, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32297444
7.
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Oncologist
; 25(7): e1077-e1082, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32272501
8.
Post-procedure protocol to facilitate next-day discharge: Results of the multidisciplinary, multimodality but minimalist TAVR study.
Catheter Cardiovasc Interv
; 96(2): 450-458, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31785087
9.
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Curr Oncol Rep
; 22(11): 116, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32851542
10.
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Oncologist
; 24(1): 103-109, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30120163
11.
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 19(2): 229-239, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361469
12.
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Oncologist
; 23(3): 353-359, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242281
13.
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Oncologist
; 23(4): 496-500, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386313
14.
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.
Oncologist
; 23(6): 740-745, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438093
15.
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Oncologist
; 22(7): 873-878, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533473
16.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Oncologist
; 22(11): 1392-1399, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835513
17.
End-stage renal disease and severe aortic stenosis: Does valve replacement improve one-year outcomes?
Catheter Cardiovasc Interv
; 89(6): 1109-1115, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211605
18.
Does minimalist transfemoral transcatheter aortic valve replacement produce better survival in patients with severe chronic obstructive pulmonary disease?
Catheter Cardiovasc Interv
; 89(4): 775-780, 2017 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27862901
19.
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
J Pharmacokinet Pharmacodyn
; 44(5): 403-414, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573468
20.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Oncologist
; 21(5): 643-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27026676